Cargando…

Patent Foramen Ovale Treatment Strategies Correspond to an Index Predicting Pathogenicity

Background: Percutaneous closure of patent foramen ovale (PFO) in patients with cryptogenic stroke (CS) may reduce the risk of recurrent stroke. By performing closure only in those with high risk of recurrent PFO related strokes, patient selection may be improved. The Risk of Paradoxical Embolism (R...

Descripción completa

Detalles Bibliográficos
Autores principales: Parr, Christopher, Liu, Shuangbo, Perija, Brittany, Shaikh, Nasir, Kass, Malek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6666847/
https://www.ncbi.nlm.nih.gov/pubmed/31367496
http://dx.doi.org/10.7759/cureus.4778
_version_ 1783439988232290304
author Parr, Christopher
Liu, Shuangbo
Perija, Brittany
Shaikh, Nasir
Kass, Malek
author_facet Parr, Christopher
Liu, Shuangbo
Perija, Brittany
Shaikh, Nasir
Kass, Malek
author_sort Parr, Christopher
collection PubMed
description Background: Percutaneous closure of patent foramen ovale (PFO) in patients with cryptogenic stroke (CS) may reduce the risk of recurrent stroke. By performing closure only in those with high risk of recurrent PFO related strokes, patient selection may be improved. The Risk of Paradoxical Embolism (RoPE) score is a point-based index developed to estimate the probability that the index CS was attributable to patent foramen ovale. We aimed to evaluate whether management strategies using conventional clinical judgement for patients with CS and PFO corresponded with RoPE scores. Methods: We performed a single-centre retrospective chart review of adult patients with CS or transient ischemic attack who were evaluated for PFO closure from January 1, 2011 to December 31, 2017. Patients were categorized based on the treatment strategy of percutaneous closure or medical management. RoPE scores were computed and clinical outcomes evaluated. Results: A total of 154 patients were included: 63 patients underwent percutaneous closure and 91 patients were treated medically. Mean RoPE scores for closure and medical groups were 6.9±1.5 and 4.7±1.9, respectively (p<0.001). For patients who underwent percutaneous closure, successful device delivery was achieved in all patients and there were no immediate complications. Conclusion: In this single-centre study, patients selected for percutaneous PFO closure based on conventional clinical judgement were more likely to have elevated PFO attributable risk, based on the RoPE score.
format Online
Article
Text
id pubmed-6666847
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-66668472019-07-31 Patent Foramen Ovale Treatment Strategies Correspond to an Index Predicting Pathogenicity Parr, Christopher Liu, Shuangbo Perija, Brittany Shaikh, Nasir Kass, Malek Cureus Cardiology Background: Percutaneous closure of patent foramen ovale (PFO) in patients with cryptogenic stroke (CS) may reduce the risk of recurrent stroke. By performing closure only in those with high risk of recurrent PFO related strokes, patient selection may be improved. The Risk of Paradoxical Embolism (RoPE) score is a point-based index developed to estimate the probability that the index CS was attributable to patent foramen ovale. We aimed to evaluate whether management strategies using conventional clinical judgement for patients with CS and PFO corresponded with RoPE scores. Methods: We performed a single-centre retrospective chart review of adult patients with CS or transient ischemic attack who were evaluated for PFO closure from January 1, 2011 to December 31, 2017. Patients were categorized based on the treatment strategy of percutaneous closure or medical management. RoPE scores were computed and clinical outcomes evaluated. Results: A total of 154 patients were included: 63 patients underwent percutaneous closure and 91 patients were treated medically. Mean RoPE scores for closure and medical groups were 6.9±1.5 and 4.7±1.9, respectively (p<0.001). For patients who underwent percutaneous closure, successful device delivery was achieved in all patients and there were no immediate complications. Conclusion: In this single-centre study, patients selected for percutaneous PFO closure based on conventional clinical judgement were more likely to have elevated PFO attributable risk, based on the RoPE score. Cureus 2019-05-30 /pmc/articles/PMC6666847/ /pubmed/31367496 http://dx.doi.org/10.7759/cureus.4778 Text en Copyright © 2019, Parr et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Cardiology
Parr, Christopher
Liu, Shuangbo
Perija, Brittany
Shaikh, Nasir
Kass, Malek
Patent Foramen Ovale Treatment Strategies Correspond to an Index Predicting Pathogenicity
title Patent Foramen Ovale Treatment Strategies Correspond to an Index Predicting Pathogenicity
title_full Patent Foramen Ovale Treatment Strategies Correspond to an Index Predicting Pathogenicity
title_fullStr Patent Foramen Ovale Treatment Strategies Correspond to an Index Predicting Pathogenicity
title_full_unstemmed Patent Foramen Ovale Treatment Strategies Correspond to an Index Predicting Pathogenicity
title_short Patent Foramen Ovale Treatment Strategies Correspond to an Index Predicting Pathogenicity
title_sort patent foramen ovale treatment strategies correspond to an index predicting pathogenicity
topic Cardiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6666847/
https://www.ncbi.nlm.nih.gov/pubmed/31367496
http://dx.doi.org/10.7759/cureus.4778
work_keys_str_mv AT parrchristopher patentforamenovaletreatmentstrategiescorrespondtoanindexpredictingpathogenicity
AT liushuangbo patentforamenovaletreatmentstrategiescorrespondtoanindexpredictingpathogenicity
AT perijabrittany patentforamenovaletreatmentstrategiescorrespondtoanindexpredictingpathogenicity
AT shaikhnasir patentforamenovaletreatmentstrategiescorrespondtoanindexpredictingpathogenicity
AT kassmalek patentforamenovaletreatmentstrategiescorrespondtoanindexpredictingpathogenicity